Home  /  Resource Library  /  Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

Study examined the efficacy and safety of polatuzumab vedotin for the treatment of relapsed diffuse large b-cell lymphoma in Asian populations.